OBJECTIVE: To assess the effectiveness of @entity717 ( @entity717 ) to manage @entity5 . To describe the adverse events (AEs) associated with @entity717 . SETTING: Thirty-nine tertiary hospital services. @entity1 : Sixty-seven oncological @entity1 with @entity5 treated at outpatient clinics. INTERVENTION: Prospective multicenter study. @entity158 intensity was scored using a Numerical Rating Scale (NRS) of 0-10. @entity158 ( @entity158 ) intensity in the last 24 hours, @entity158 ( @entity158 ), and the number of episodes of @entity158 on the days before and 1 week after @entity717 were assessed. The pre- @entity717 and post- @entity717 opioid were recorded. The presence and intensity of any AEs occurring after @entity717 were also recorded. RESULTS: In the 67 @entity1 evaluated, 75 ORs were recorded. In all cases, the main reason for @entity717 was poor @entity158 control. @entity158 intensity decreased by >= 2 points after @entity717 in 75.4 percent and 57.8 percent of cases for @entity158 and @entity158 , respectively. If the initial NRS score was >= 4, a decrease below <4 accounted for 50.9 percent and 32.3 percent of cases for @entity158 and @entity158 , respectively. The number of episodes of @entity158 also decreased significantly (p<0.001). A total of 107 AEs were reported, most of which were mild in intensity, with @entity344 predominating. CONCLUSIONS: Opioid rotation appears to be both safe and effective in the management of basal and breakthrough @entity5 .

Effectiveness of @entity717 in the control of XXXX : The ROTODOL Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related pain', 'cancer pain'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal symptoms'] @entity158 :: ('MESH:D010146', 'Disease') :: ['AP', 'Pain', 'breakthrough pain', 'BTP', 'pain', 'Average pain'] @entity717 :: ('MESH:D009069', 'Disease') :: ['OR', 'opioid rotation']
@entity5 :: (MESH:D009369,Disease) :: ['cancer pain']
